Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A new combination of long-acting insulin plus a GLP-1 compound is in phase 3 trials and the results are outstanding....
IDegLira, a fixed-ratio combination of insulin degludec and the glucagon like peptide-1 agonist liraglutide, outperformed each medication alone in a 26 week pivotal phase III clinical trial. Patients on IDegLira averaged a 1.91% drop to an HbA1c of 6.4%, compared to1.44% drop to 6.9% with insulin degludec and the 1.28% reduction to an HbA1c of 7.0% with liraglutide. In addition, the IDegLira group fared significantly better in terms of 32% lower rate of hypoglycemic events compared to the insulin degludec group.
http://www.diabetesincontrol.com/ar...037-insulin-glp-1-combination-therapy-results
IDegLira, a fixed-ratio combination of insulin degludec and the glucagon like peptide-1 agonist liraglutide, outperformed each medication alone in a 26 week pivotal phase III clinical trial. Patients on IDegLira averaged a 1.91% drop to an HbA1c of 6.4%, compared to1.44% drop to 6.9% with insulin degludec and the 1.28% reduction to an HbA1c of 7.0% with liraglutide. In addition, the IDegLira group fared significantly better in terms of 32% lower rate of hypoglycemic events compared to the insulin degludec group.
http://www.diabetesincontrol.com/ar...037-insulin-glp-1-combination-therapy-results